LifeArc and UK DRI Partnered to Accelerate New Development Treatments for Dementia

BUSINESS HEALTHCARE

The LifeArc and the UK Dementia Research Institute (UK DRI) has launched a new partnership for the purpose of accelerating the development of the new diagnostic tests, along with the treatments and devices from the scientific research discoveries for providing benefits to the people with dementia, which around 900,000 people are living with in the United Kingdom.

In the partnership of five years, there is a commitment of 30 million pounds by the medical research charity ‘LifeArc’ to the UK DRI for the purpose of supporting dementia research at the six UK host universities where the institute is located.

Through the fundamental discovery science, the researchers of UK DRI have been revealing the mechanisms underpinning the neurodegenerative diseases that is causing dementia. The funding is going to be used for the purpose of translating these scientific discoveries into the new diagnostic tests, treatments and devices, and these conditions are also including Alzheimer’s disease, motor neuron disease and Parkinson’s disease.

See also  The CDC is Discontinuing Country-Specific COVID-19 Travel Health Notices in the US

As the research has revealed much more about these diseases and still there are no effective ways for the purpose of preventing them from progressing. Dr. Dave Powell, chief scientific officer of LifeArc said, the Great strides have been made in the research of dementia in recent years but there has been much more that is needed to be done.